AGE-ADJUSTED YEARS OF POTENTIAL LIFE LOST (YPLL) RATES DUE TO OVARIAN CANCER IN CHILE DURING 2002-2019.





Authors: dos Santos, FM¹, Caputo, M¹, Romero, JF¹. Affiliations: ¹Medical Department, GSK, Santiago, Chile

Background & Aims

Since 2013, Ovarian Cancer (OC) was included in the Chilean Explicit Health Guarantees (GES) program, guaranteeing diagnosis and treatment (1). Advances in treatment and changes in clinical practice may impact on OC mortality. Therefore, the objective of this study was to evaluate the Years of Potential Life Lost (YPLL) due to OC in Chile considering 2002-2019 period.

Methods



Deaths: ICD-10 C56, C57.0, C48.1,

C48.2 (2)

Population projection: National

Statistics Institute (3).



Age-adjusted YPLL rates/100,000 habitants were estimated for Chile and its 7 most populous regions by using the direct method, applying age-specific rates in a population of interest to a standardized age distribution using the 2022 population as reference and considering 80-year life expectancy.



Postmenopausal women (50-64)



and 3rd age were (65-79)analyzed.



The total period was evaluated and stratified into 2002-2013 (pre-GES) and 2014-2019 (post-GES) and assessed qualitative.


Conclusions



Mean AA-YPLL rates post-GES had an overall decrease. However, in certain regions rising rates were observed in recent years. These results must be further studied to understand the causes and design appropriate public health actions.

Results

Years of Potential Life Lost (considering 80 years as life expectancy)



The highest rate of AA-YPLL are in the post-menopause (50-64y) group due to the highest frequency of death.

Age group	Average AA-YPLL per 100.000 habs		% of
	Pre-GES: 2002-2013	Post-GES: 2014-2019	% of Change
50-64	44,60	43,22	-3%
65-79	19,08	19,16	0,4%

Postmenopausal and 3rd age AA-YPLL rates description in the 7 most populous Chilean regions. Results are shown as mean Pre-GES vs Post-GES (% of change)

50-64y **POST - GES GES METROPOLITANA** 42.4 vs 40.7 44 35 48 43 48 34 34 40 47 45 43 48 35 45 44 41 42 37 Slowly falling (-4%) **VALPARAÍSO** 54 42 41 49 42 40 36 53 58 44 27 53 51 37 56 57 51 43 44.8 vs 49.3 Slowly falling in (10%) recent years BÍOBÍO 50.0 vs 59.5 No specific trend (19%) MAULE 43 31 45 38 33 55 37 54 41 36 32 58 40.1 vs 42.5 Slowly falling, (6%) then went up LA ARAUCANÍA 43 43 31 46 45 48 45.4 vs 33.8 Constant, with (-26%)less variation 62 66 O'HIGGINS 39 35 40 56.4 vs 42.7 Increasing rapidly (-24%)

2002 2003 2004 2005 2005 2006 2010 2010 2013 2015 2015 2016 2016 2017 2018 2019 2019

POST - GES 65-79y **GES METROPOLITANA** 20 20 19 18 17 17 21 22 22 21 19 17 22 18 21 16 15 19.1 vs 19.0 Slowly falling (-1%)**VALPARAÍSO** 27 29 20 18 19 26 22 20 25 27 19 13 16.1 vs 17.3 Falling in (8%) recent years BÍOBÍO 22.3 vs 26.2 Constant, then (17%) increasing recently **MAULE** 23 23 19 11 14 15.4 vs 15.9 0 12 7 15 15 14 14 Falling, (3%) then went up 33 30 LA ARAUCANÍA 21.3 vs 19.7 Increasing (-8%)O'HIGGINS 19.2 vs 18.0 Increasing, then a 14 17 16 15 break reducing rates (-6%) but came back to previous values recently

References:

lud/index/71.

- 1. Minister of Health. GES 71. Cáncer de ovario epitelial. [cited 2024 Sep 30]. Available at: https://auge.minsal.cl/problemasdesa-
- 2. Minister of Health. Department of Health Statistics and Information. [cited 2024 Sep 30]. Available at: https://deis.minsal.cl/.

Presenting author: Felipe Moraes dos Santos, felipe.s.moraes@gsk.com

3. National Istitute of Statistics. Population Projections. [cited 2024 Sep 30]. Available at: https://www.ine.gob.cl/estadisticas/so-

ciales/demografia-y-vitales/proyecciones-de-poblacion ISPOR Europe | 17-20 Nov 2024 | Barcelona, Spain

Acknowledgements:

We would like to acknowledge Elif Coskuncay from GSK, London, UK for her inputs in the poster, Igloolab for their support on poster design and OPEN Health Communications for the coordination of the review & approval, which was funded by GSK, in accordance with Good Publication Practice (GPP) guidelines (www.ismpp.org/gpp-2022).

2002 2003 2004 2005 2005 2007 2007 2013 2013 2015 2016 2016 2017 2018 2018

Disclosures:

This study was funded by GSK (study ID: 222625). Felipe Moraes and Milva Caputo are employed by GSK and do not hold financial equities in GSK. Jose Romero is an employee of GSK and holds financial equities in GSK.